Tumour mutational burden in treatment-resistant tumours - Authors' reply

Lancet Oncol. 2020 Dec;21(12):e552. doi: 10.1016/S1470-2045(20)30697-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Biomarkers, Tumor
  • Humans
  • Neoplasms*
  • Prospective Studies

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • pembrolizumab